20 years of excellence in MS research

This year marks the 20th Year of MS Australia’s national research program. Over the past 20 years we have invested over $54m in MS research, supercharging Australian MS research and encouraging and supporting collaboration across the sector.

Explore 20 years of excellence in MS research and revisit some of the key milestones across those two decades.

2004

Research arm of MSA established, with Simon McKeon as inaugural Chairman.

2004

2007

2007

First Progress in MS Research Conference held.

2008

Launch of the Australian and New Zealand MS Genetics Consortium to understand how genes contribute to MS risk and progression.

2008

2008

2008

MSA Brain Bank was launched with Sydney University to support MS research with high quality brain tissue.

2010

The first intravenous infusion DMT, natalizumab (Tysabri), listed on the PBS.

2010

2010

2010

MSA's Clinical Trials Network launched alongside a dedicated website listing all available MS trials across Australia and New Zealand.

2010

The first Economic Impact of Multiple Sclerosis report released.

2010

2011

2011

The first oral (capsule) DMT, fingolimod (Gilenya), listed on the PBS.

2011

Australian MS AHSCT Registry established.

2011

2012

2012

Launch of Kiss Goodbye To MS fundraising platform for MS research.

2013

The MSA-funded Vitamin D MS Prevention Clinical Trial launched.

2013

2013

2013

MSA research identifies 48 new genetic changes that affect the risk of developing MS.

2014

MS Australia becomes a founding member of the International Progressive MS Alliance, a global collaboration between MS researchers and organisations committed to tackling progressive MS.

2014

2016

2016

Launch of the first Research Priorities Survey to seek feedback from the MS community on our current and future research strategy.

2019

Launch of The May 50K campaign, raising over $2.1m to fund vital MS research - now an annual and global event.

2019

2019

2019

MSA’s advocacy helps lead to PBS listing of siponimod (Mayzent), the first DMT for secondary progressive MS in Australia.

2020

MSA releases the first evidence-based lifestyle management guidelines for MS in Australia.

2020

2020

2020

Work starts on InforMS, an online MS Patient-Centred Portal that will facilitate self-management of healthcare by people with MS and shared decision making with their care team.

2022

Record $6.9m allocated by MS Australia for MS research.

2022

2022

2022

Landmark report on MS Nurse Care in Australia released.

2022

Results from the Vitamin D MS Prevention Clinical Trial released.

2022

2022

2022

Federal Budget allocates $18m for MS research following MSA advocacy.

2023

PLATYPUS, the first adaptive clinical trial for Australians with MS announced to fast-track repurposed treatments for nerve protection and myelin repair in people with progressive MS.

2023

2023

2023

MSA joins with many MS organisations from around the world to declare their collective commitment to a global research strategy to cure MS.

2023

Australian research identifies the first genetic marker for MS severity, opening the door to treatments for long-term disability.

2023

2024

2024

Launch of a new report reveals lengthy time to MS diagnosis and underscores the urgent need for greater investment in research and increased awareness of the disease.

Read More

Newsletter subscription

  • Enter your details

20 years of excellence in MS research